来氟米特片联合白芍总苷胶囊治疗类风湿关节炎的疗效观察

摘要

目的：分析来氟米特联合白芍总苷治疗类风湿关节炎的临床疗效及不良反应。方法：选取2012年6月—2014年6月收治的100例类风湿关节炎患者，分为治疗组50例（来氟米特联合白芍总苷）和对照组50例（单用来氟米特）。观察治疗前及治疗12周后两组患者各项指标变化及不良反应。结果：治疗12周后，治疗组总有效率为94％，对照组总有效率为78％，治疗后两组患者关节肿胀数、关节压痛数、晨僵时间、疼痛视觉模拟（VAS）评分、红细胞沉降率（ESR）、C 反应蛋白（CRP）、类风湿因子（RF）指标均明显下降（P ＜0.05），且治疗组下降值较对照组更明显，差异有统计学意义（P ＜0.05）；治疗后治疗组不良反应发生率为8％，对照组不良反应发生率为26％，且对照组的肝功能损害发生率明显高于治疗组（P ＜0.05）。结论：来氟米特联合白芍总苷胶囊治疗类风湿关节炎疗效显著，不良反应较少。%Objective:To investigate the clinical efficacy and safety of leflunomide combine with total glucosides of paeony capsules for patients with rheumatoid arthritis. Methods:One hundred patients with rheumatoid arthritis from June 2012 to June 2014 were randomly divided into the treatment group(n = 50)and the control group(n = 50). The patients in the treatment group accepted the treatment of leflunomide and total glucosides of paeony capsules,the control group received the treatment of leflunomide only. Indicators and adverse reaction were evaluated before and after the treatment. Results:After the 12 weeks of clinical treatment,the effective rate in treatment group was 94% ,otherwise in control group was 78% ,the clinical symptoms, visual analogue scale(VAS),erythrocyte sedimentation rate(ESR),C - reactive protein(CRP),rheumatoid factor(RF)in the treatment group significantly lower than that in the control group(P < 0. 05),the rate of adverse effect in treatment group was 8% ,and 26% in control group,the liver dysfunction in control group was higher than treatment group(P < 0. 05). Conclu-sion:The effect of treating rheumatoid arthritis with leflunomide and total glucosides of paeony capsules is safe and valuable.